Senseonics gains expanded Medicare coverage for implantable CGM
February 13, 2024
Three Medicare Administrative Contractors will start covering the Eversense E3 CGM for people who only take basal insulin.
Three Medicare Administrative Contractors will start covering the Eversense E3 CGM for people who only take basal insulin.
Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq AP-Dx. The digital pathology solution was cleared for the purpose of primary diagnosis.
Researchers at the University of Toronto’s Donnelly Center for Cellular and Biomolecular Research have found nearly one million new exons—stretches of DNA that are expressed in mature RNA—in the human genome.
The sticky, wearable sensor could help identify early signs of acute liver failure.
Viz.ai announced that it received FDA 510(k) clearance for its Viz ICH Plus algorithm for providing volume measurements of brain bleeds.
The clearance positions Insulet to sell the integrated Type 1 diabetes product in Europe beginning in the first half of the year.
BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”
Fresenius Medical Care announced today that it received FDA clearance for its 5008X hemodialysis system.
FDA backing for the Wavewriter SCS systems allows the company to challenge Abbott and Nevro.
New technique made human T cells 100 times more potent at killing cancer cells